|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.72 SEK | -0.71% |
|
-5.54% | +1.25% |
| 16/01 | UBS Lowers Price Target for Vimian to 34 Kronor (Previously 39), Maintains Neutral Rating | FW |
| 12/01 | Head of Specialty Pharma Segment to Leave Vimian | FW |
| Capitalization | 151.84Cr 176.12Cr 141.35Cr 131.59Cr 245Cr 16TCr 263.6Cr 1.63TCr 641.11Cr 7.62TCr 660.48Cr 646.88Cr 28TCr | P/E ratio 2025 * |
47x | P/E ratio 2026 * | 26.2x |
|---|---|---|---|---|---|
| Enterprise value | 170.5Cr 197.77Cr 158.72Cr 147.76Cr 275.12Cr 18TCr 296Cr 1.83TCr 719.9Cr 8.56TCr 741.65Cr 726.38Cr 31TCr | EV / Sales 2025 * |
4.02x | EV / Sales 2026 * | 3.6x |
| Free-Float |
33.03% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Vimian Group AB
| 1 day | -0.71% | ||
| 1 week | -5.54% | ||
| Current month | +1.25% | ||
| 1 month | +5.21% | ||
| 3 months | +4.70% | ||
| 6 months | -28.89% | ||
| Current year | +1.25% |
| 1 week | 30.2 |  | 32.94 |
| 1 month | 28.38 | | 32.94 |
| Current year | 29.9 | | 32.94 |
| 1 year | 27.8 | | 47.3 |
| 3 years | 20.08 | | 47.3 |
| 5 years | 20.08 | | 123.4 |
| 10 years | 20.08 | | 123.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 43 | 24/11/2025 | |
| Chief Executive Officer | 47 | 17/07/2025 | |
| Investor Relations Contact | 45 | 01/09/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 49 | 01/01/2021 | |
Theodor Bonnier
BRD | Director/Board Member | 37 | 01/01/2021 |
Petra Rumpf
BRD | Director/Board Member | 59 | 01/01/2022 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | -5.54% | -23.10% | -0.78% | 176.12Cr | |
| -0.50% | -1.98% | -24.86% | -21.88% | 5.49TCr | |
| +1.45% | +4.52% | +104.08% | +91.19% | 1.22TCr | |
| -0.55% | -1.43% | -23.90% | +3.70% | 396.9Cr | |
| -0.83% | -1.92% | +15.91% | +38.64% | 346.93Cr | |
| +3.53% | +1.21% | +172.60% | +71.64% | 276.16Cr | |
| +2.52% | +4.13% | +97.26% | +179.39% | 166.47Cr | |
| +0.90% | +1.26% | +8.86% | +3.17% | 131.3Cr | |
| -0.47% | -2.07% | +24.05% | -12.09% | 116.44Cr | |
| -0.63% | -2.84% | +22.97% | -38.47% | 115.33Cr | |
| Average | +0.47% | -0.33% | +37.39% | +31.45% | 843.77Cr | |
| Weighted average by Cap. | -0.03% | -0.79% | +6.25% | +5.91% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 42Cr 49Cr 40Cr 37Cr 68Cr 4.47TCr 74Cr 454.37Cr 179.16Cr 2.13TCr 184.57Cr 180.78Cr 7.78TCr | 46Cr 54Cr 43Cr 40Cr 75Cr 4.87TCr 80Cr 495.87Cr 195.52Cr 2.32TCr 201.43Cr 197.29Cr 8.49TCr |
| Net income | 3.01Cr 3.49Cr 2.8Cr 2.61Cr 4.85Cr 316.6Cr 5.22Cr 32Cr 13Cr 151.02Cr 13Cr 13Cr 551.44Cr | 5.69Cr 6.61Cr 5.3Cr 4.94Cr 9.19Cr 599.36Cr 9.89Cr 61Cr 24Cr 285.89Cr 25Cr 24Cr 1.04TCr |
| Net Debt | 19Cr 22Cr 17Cr 16Cr 30Cr 1.96TCr 32Cr 199.82Cr 79Cr 936.8Cr 81Cr 80Cr 3.42TCr | 15Cr 17Cr 14Cr 13Cr 24Cr 1.55TCr 26Cr 157.86Cr 62Cr 740.08Cr 64Cr 63Cr 2.7TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/26/16 | 30.72 kr | -0.71% | 2,07,495 |
| 15/26/15 | 30.94 kr | -1.15% | 2,09,173 |
| 14/26/14 | 31.30 kr | -2.07% | 2,62,387 |
| 13/26/13 | 31.96 kr | -1.60% | 1,56,355 |
| 12/26/12 | 32.48 kr | -0.12% | 2,61,758 |
Delayed Quote Nasdaq Stockholm, January 16, 2026 at 10:30 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VIMIAN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition